Wen Jinghao, Lan Zehao, He Liting, Long Hai
Department of Dermatology, Hunan Key Laboratory of Medical Epigenomics, The Second Xiangya Hospital, Central South University, Changsha, 410011, China.
Clin Rev Allergy Immunol. 2025 Jun 20;68(1):60. doi: 10.1007/s12016-025-09065-y.
Mast cells play a key role in innate immunity by mediating host defense and maintaining tissue balance. They achieve this through the controlled release of bioactive mediators such as histamine, heparin, leukotrienes, and prostaglandin D2. Their functional diversity is enabled by multiple receptor systems that coordinate differentiation, maturation, and degranulation processes through tissue-specific microenvironmental signals. Pathological activation through allergen exposure or intrinsic regulatory dysfunction contributes to various disorders, ranging from allergic conditions to autoimmune diseases and chronic inflammatory states. Current anti-mast cell therapies have expanded from broad-spectrum antihistamines to more precise treatments targeting IgE or its surface receptors expressed on mast cells. Emerging insights into activation mechanisms of mast cells, particularly structural and functional characterization of critical receptors, have accelerated the development of novel therapeutic interventions. This review discusses the advances in molecular mechanisms of mast cell activation and summarizes how these findings redefine our understanding of disease progression and emerging therapeutic targets.
肥大细胞通过介导宿主防御和维持组织平衡在固有免疫中发挥关键作用。它们通过控制释放生物活性介质(如组胺、肝素、白三烯和前列腺素D2)来实现这一点。它们的功能多样性由多个受体系统实现,这些受体系统通过组织特异性微环境信号协调分化、成熟和脱颗粒过程。通过过敏原暴露或内在调节功能障碍引起的病理激活会导致各种疾病,从过敏状态到自身免疫性疾病和慢性炎症状态。目前的抗肥大细胞疗法已从广谱抗组胺药扩展到针对IgE或肥大细胞上表达的其表面受体的更精确治疗。对肥大细胞激活机制的新见解,特别是关键受体的结构和功能特征,加速了新型治疗干预措施的开发。本综述讨论了肥大细胞激活分子机制的进展,并总结了这些发现如何重新定义我们对疾病进展和新兴治疗靶点的理解。